UCB's Vimpat prevails in patent challenge--but IPR threat still lurks

Justice statue with sword and scales

It’s a great day for Belgium’s UCB pharma, thanks to a U.S. District Court patent ruling. In fact, it’s one of the company's best days in years.

Sunday, UCB announced that a Delaware District Court had rejected challenges to its patent on anti-seizure drug Vimpat--one of four key products for the Brussels-based drugmaker.

And investors cheered the news, sending UCB shares to the highest height they’ve reached since 2009.

With the decision, Vimpat’s IP shield is now safe through 2022--at least, for now--and UCB is expecting big things from the med before that time comes. The company’s expecting the med to rake in peak sales of more than €1.2 billion by 2020, it said in its annual report.

In 2015, it generated €679 million in annual sales, joining products Cimzia, Neupro and Keppra to combine for 77% of UCB’s global net sales.

UCB isn’t totally out of the woods, though. In late May, New York-based generics maker Argentum Pharmaceuticals won an inter partes review of Vimpat’s patent protection by the U.S. Patent & Trademark Office (PTO)’s Patent Trial & Appeal Board (PTAB). And that decision may not be handed down until next May.

Still, court’s decision is a “long-awaited sentiment boost” for UCB, whose shares had fallen by about 17% so far this year, Citigroup analysts wrote in a Monday note seen by Bloomberg. Despite the lingering risk of patent invalidation, they wrote, “we expect market confidence to improve.”

- read UCB's release
- get more from Bloomberg

Related Articles:
Belgium's UCB calls it quits on $1.53B sale of U.S. generic drug unit
UCB joins pharma's slimdown craze, unloads U.S. generic drug business for $1.53B
UCB taps biopharma chief to step up to CEO job, prep for new launches


Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.